Chardan Maintains Monopar 'Buy' Rating and Issues Earnings Forecast

Summary

Chardan Capital has issued a financial projection for Monopar Therapeutics (NASDAQ: MNPR), predicting an earnings per share (EPS) of ($2.02) for the fiscal year 2025 and maintaining a ‘Buy’ rating with a target price of $60.00 per share. The current consensus estimate stands at an EPS of ($1.65). For 2026, the EPS is estimated to be ($2.87). Monopar’s stock has been volatile, with a recent trading price of $33.60 and a market capitalization of $205.63 million. Institutional investors have increased their holdings in the companyMarket Beat. Additionally, in previous reports, HC Wainwright reaffirmed a ‘Buy’ rating with a $40.00 target price, while Jones Trading rated it as ‘Hold’Market Beat.

Impact Analysis

The event is classified as a company-level event due to its specific focus on Monopar Therapeutics and the direct implications of Chardan Capital’s report. The immediate first-order effect is a potential increase in investor interest and positive market sentiment due to the ‘Buy’ rating and the higher-than-consensus earnings forecast for 2025, which could lead to a stock price increase towards the target price of $60.00. Institutional investor interest, as indicated by increased holdings, further supports this positive outlookMarket Beat. The second-order effects could involve increased competition attention in the biotech sector, influencing both peer assessments and strategic partnerships. Investment opportunities primarily revolve around potential stock appreciation for Monopar Therapeutics as well as options strategies to capitalize on expected volatility and price movements. However, investors should also consider risks associated with stock fluctuations and the execution of Monopar’s growth strategy in achieving the projected earningsMarket Beat.